Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms Raffaela.

Slides:

Advertisements

Similar presentations

Volume 11, Pages (September 2016)

Advertisements

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,

Volume 11, Pages (September 2016)

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut Claudia.

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Identification of common allergenic structures in mugwort and ragweed pollen Reinhold Hirschwehr, MDa, Claudia Heppner, MSca, Susanne Spitzauer, MDb,

Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin)

Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments Raffaela Campana, PhD, Katharina.

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut Claudia.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy Margarete Focke-Tejkl, PhD, Milena.

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy Raphaela.

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis Friedrich Horak, MD, Kamal D.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber Friedrich Horak, MD, Petra.

Recombinant allergens: What does the future hold?

In vivo allergenic activity of a hypoallergenic mutant of the major fish allergen Cyp c 1 evaluated by means of skin testing Nikolaos Douladiris, MD,

Component-resolved diagnosis of baker's allergy based on specific IgE to recombinant wheat flour proteins∗ Ingrid Sander, PhD, Hans-Peter Rihs, PhD,

Molecular determinants of allergen-induced effector cell degranulation

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults Christian Lupinek, MD,

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.

Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort Anna.

Component-Resolved Diagnosis (CRD) of Type I Allergy with Recombinant Grass and Tree Pollen Allergens by Skin Testing Susanne Heiss, Rudolf Valenta

Allergen microarray detects high prevalence of asymptomatic IgE sensitizations to tropical pollen-derived carbohydrates Clarissa R. Cabauatan, PhD, Christian.

Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5 Margarete Focke-Tejkl, PhD, Raffaela Campana, PhD, Renate.

Patients Allergic to Fish Tolerate Ray Based on the Low Allergenicity of Its Parvalbumin Tanja Kalic, MSc, Francoise Morel-Codreanu, MD, Christian Radauer,

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial Adam M. Chaker, MD, Mohamed H. Shamji,

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen:

Journal of Allergy and Clinical Immunology

Early decreases in blood eosinophil levels with reslizumab

Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens Brian P. Vickery, MD, Jing Lin, PhD, Michael Kulis, PhD, Zhiyan Fu,

Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens Stef J. Koppelman, PhD, Aurélie Peillon, MSc, Wenceslas.

Kerstin Bauermeister, MSc, Barbara K

Determination of IgE and IgG reactivity to more than 170 allergen molecules in paper- dried blood spots Victoria Garib, MD, PhD, Eva Rigler, MD, PhD,

Underestimation of house dust mite–specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs Huey-Jy Huang, MSc, Yvonne Resch-Marat,

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy Kuan-Wei Chen, PhD, Petra Zieglmayer,

Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children Yvonne Resch, MSc, Sven Michel, MSc, Michael Kabesch, MD,

Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen– allergic patients Verena Niederberger, MD, Katharina Marth, MD,

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

CD23 surface density on B cells is associated with IgE levels and determines IgE- facilitated allergen uptake, as well as activation of allergen-specific.

A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS Katarzyna Niespodziana, MSc, Margarete Focke-Tejkl, PhD, Birgit.

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Recombinant allergen-based IgE testing to distinguish bee and wasp allergy Irene Mittermann, PhD, Mihaela Zidarn, MD, Mira Silar, PhD, Zora Markovic-Housley,

Cat IgA, representative of new carbohydrate cross-reactive allergens

Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly Raffaela Campana, PhD, Susanne Vrtala,

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

The natural history of milk allergy in an observational cohort

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Mast cell–derived proteases control allergic inflammation through cleavage of IgE Ingrid Rauter, PhD, Maria-Theresa Krauth, MD, Kerstin Westritschnig,

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy Teresa E. Twaroch, MSc, Margit Focke, PhD, Vera Civaj, Milena.

Monitoring the epitope recognition profiles of IgE, IgG1, and IgG4 during birch pollen immunotherapy Barbara Gepp, MSc, Nina Lengger, BMA, Christian.

Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence Marit Westman, MD, Christian Lupinek,

Presentation transcript:

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms Raffaela Campana, PhD, Katharina Marth, MD, Petra Zieglmayer, MD, Milena Weber, MSc, Christian Lupinek, MD, Yury Zhernov, MD, PhD, Olga Elisyutina, MD, Musa Khaitov, MD, PhD, Eva Rigler, MD, PhD, Kerstin Westritschnig, MD, Uwe Berger, MBA, Martin Wolkersdorfer, PhD, Fritz Horak, MD, Friedrich Horak, MD, Rudolf Valenta, MD Journal of Allergy and Clinical Immunology Volume 143, Issue 3, Pages 1258-1261 (March 2019) DOI: 10.1016/j.jaci.2018.11.011 Copyright © 2018 The Authors Terms and Conditions

Fig 1 Scheme, time course of study, and development of specific IgG responses. A, The study was conducted over a period of 2 years (x-axis: weeks). The 13 study visits are indicated as well as the time points of vaccination (I-IV), blood sampling, and skin testing. Development of specific IgG responses (y-axes: OD increases compared with baseline) against, Bet v 1 (B), F1 (C), F2 (D) birch pollen–specific IgE (E) (y-axis: kUA/L), and birch pollen–induced wheal reactions (F) (y-axis: mm2) during the 2 years of the study (x-axes: wk/visits) in the active group (grey) and the placebo group (black). Time points of vaccination and pollen seasons (boxed) are indicated. SPT, Skin prick test. Journal of Allergy and Clinical Immunology 2019 143, 1258-1261DOI: (10.1016/j.jaci.2018.11.011) Copyright © 2018 The Authors Terms and Conditions

Fig 2 Inhibition of IgE binding to Bet v 1 by treatment-induced antibodies in patients with allergy. Shown are the percentages of inhibition as box plots with median and lower and upper quartiles of IgE binding of patients (BPA 1-11) obtained by preincubation of ELISA plate-bound Bet v 1 with sera from actively treated (black) or placebo-treated subjects (grey) taken at the different visits indicated (x-axes) (Table E5). BPA, Birch pollen allergic patient. Journal of Allergy and Clinical Immunology 2019 143, 1258-1261DOI: (10.1016/j.jaci.2018.11.011) Copyright © 2018 The Authors Terms and Conditions